But at least CVT is going to get to give Ranexa one more big push.

FORBES: Magazine Article

Ranexa was tested on top of Norvasc in patients who were already benefiting the most from that drug.

FORBES: A Biotech's Big Comeback

Apart from that, the results might assure doctors that Ranexa does not cause deadly changes in heart rhythm.

FORBES: A Good Failure?

That meant that it was going to be very difficult for Ranexa to show a benefit in these patients.

FORBES: Magazine Article

The FDA approved Ranexa for use only when other anti-angina drugs have failed.

FORBES: A Good Failure?

There is still a chance that patients on Ranexa did better than those who received placebos, but the difference wasn't statistically significant.

FORBES: Magazine Article

Ranexa caused a change in the electrical rhythms of the heart.

FORBES: A Biotech's Big Comeback

The drug is approved to treat chest pain due to heart problems, but a big study failed to prove Ranexa can prevent heart attacks or extend lives.

FORBES: A Heart-Pumping Meeting

The first late-stage trial of Ranexa's potential appeared in 1999.

FORBES: A Biotech's Big Comeback

Now the debate over CVT should focus on whether the FDA will allow the company to market Ranexa as a first choice for angina patients, and whether doctors are going to buy the company's sales pitch.

FORBES: Magazine Article